A trial of low-dose PTCy with ATG/granulocyte colony-stimulating factor for patients undergoing haplo-HSCT decreased the cumulative incidence of grade III to IV aGVHD in the ATG-PTCy cohort to a rate significantly lower than that in the ATG group (5% vs 18%; P = .003) and increased the GRFS rate for patients who received low-dose PTCy.20 For cGVHD prophylaxis, the improved dose and duration of immunosuppressants increased the risk of organ dysfunction, infection, and recurrence.21 MSC therapy is a well-tolerated therapy for aGVHD and cGVHD. The gene discussed is CSF3; the disease is infection.